Navigation Links
Sensus Healthcare Announces New Professional Skin Care Line - Sensus Skin Solutions™
Date:1/24/2011

BOCA RATON, Fla., Jan. 24, 2011 /PRNewswire/ -- Sensus Healthcare is pleased to announce its Sensus Skin Solutions™ line of professional skin care products to be exclusively offered by our physician partners.

(Logo: http://photos.prnewswire.com/prnh/20110124/FL34943LOGO)

Cases of skin cancer are on the rise and are dramatically escalating as the population ages. Sensus is taking new aim at skin cancer(SM) in innovative ways. On one front, we are incorporating state-of-the-art mobile X-ray technology for cost-effective, non-invasive treatment of non-melanoma skin cancers with a 98% cure rate. Our signature product, the SRT-100™, utilizes low dose radiotherapy that goes no deeper than the thickness of the skin. On another front, we are working to prevent skin cancer by educating patients about the benefits of good skin care and offering the Sensus Skin Solutions™ professional line that is formulated to help reverse past damage, fight skin problems, and to protect skin from future damage. Our goal is to help patients in protecting their skin from the damage caused by UVA and UVB rays with our advanced titanium-based sunscreen products, together with a daily skin care line in order to maintain healthy and beautiful skin.

Proper skin care and protection are essential components in keeping skin healthy and beautiful for a longer time. Sensus knows it's never too early or too late to begin developing good skin care habits. With the Sensus Skin Solutions™ professional skin care line developed by cosmetic dermatologists and scientists, skin will be protected and renewed, and wrinkles, sun spots, and other discolorations can be diminished. Our products are all-natural, cutting-edge, fast-acting specialized formulations that are available through our physician partners. With a clinician's direction, patients can achieve beautiful, healthy skin with improved appearance and texture while protecting skin from the damaging effects of the sun.

Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated low-dose superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings. We also offer a professional skin care line, Sensus Skin Solutions™, through our physician partners for their patients. For additional information, please contact:Vicky PerezPublic Relationsvicky@sensushealthcare.com561-922-5808 Ext 108
'/>"/>

SOURCE Sensus Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sensus Healthcare Announces Strategic Partnership With Flagship Solutions Group
2. Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
3. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
4. New consensus on work-related asthma
5. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
7. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
8. Cellular Dynamics International to Present at 29th Annual JPMorgan Healthcare Conference
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. ViroPharma to Participate in the 29th Annual J.P. Morgan Healthcare Conference
11. Advanced BioHealing to Present at 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):